Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176416 | 0.93 | HTR2C (0.38) | DGKAHTR2CADRA2AADRA1AMAPT | |
| SCHEMBL29028494 | 0.93 | HTR2C (0.47) | DGKAHTR2CADRA2AADRA1AMAPT | |
| SCHEMBL6267406 | 0.93 | DGKA (0.44) | DGKAHTR2CADRA2AADRA1AMAPT | |
| SCHEMBL28289669 | 0.93 | HTR2C (0.47) | DGKAHTR2CADRA2AADRA1AMAPT | |
| SCHEMBL767599 | 0.92 | HTR2C (0.37) | DGKAHTR2CADRA2AADRA1AMAPT | |
| SCHEMBL8839165 | 0.91 | DGKA (0.52) | DGKAHTR2CMAPTNAAACYP1A2 | |
| SCHEMBL12080684 | 0.90 | DGKA (0.38) | DGKAHTR2CADRA2AADRA1AMAPT | |
| SCHEMBL1224968 | 0.89 | NAAA (0.52) | DGKAHTR2CNAAADNM1GAA | |
| SCHEMBL9323713 | 0.89 | GAA (0.46) | DGKAMAPTNAAAGAAALDH1A1 | |
| SCHEMBL28289681 | 0.88 | ADRA2A (0.43) | DGKAHTR2CADRA2AADRA1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055060-A | Virus infection inhibitor, virus-inhibiting liquid, virus-inhibiting paint, master batch for molding synthetic resin, and virus-inhibiting product | 积水化学工业株式会社 | 2026-05-15 | — | — | CN | disclosed |
| CN-122029251-A | Allergen reducing agent, allergen reducing liquid, allergen reducing paint, and masterbatch for molding synthetic resin | 积水化学工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-11822243-B2 | Negative-type photosensitive resin composition, cured film, element and display device provided with cured film, and production method therefor | TORAY INDUSTRIES, INC. (JP) | 2023-11-21 | — | — | US | disclosed |
| CN-111373325-B | Silicone resin composition, cured film, and display device | 东丽株式会社 | 2023-10-17 | — | — | CN | disclosed |
| CN-109716491-B | Method for manufacturing field effect transistor and method for manufacturing wireless communication device | 东丽株式会社 | 2023-06-09 | — | — | CN | disclosed |
| CN-111095566-B | Field effect transistor, method of manufacturing the same, wireless communication device using the same, and merchandise tag | 东丽株式会社 | 2023-05-23 | — | — | CN | disclosed |
| EP-3514822-B1 | METHOD FOR MANUFACTURING FIELD EFFECT TRANSISTOR AND METHOD FOR MANUFACTURING WIRELESS COMMUNICATION DEVICE | TORAY INDUSTRIES (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-109804310-B | Negative photosensitive resin composition, cured film, element and display device provided with cured film, and method for producing same | 东丽株式会社 | 2022-09-30 | — | — | CN | disclosed |
| CN-114460809-A | Negative photosensitive resin composition, cured film, display device provided with cured film, and method for producing same | 东丽株式会社 | 2022-05-10 | — | — | CN | disclosed |
| CN-108885399-B | Negative photosensitive resin composition, cured film, display device provided with cured film, and method for producing same | 东丽株式会社 | 2022-03-15 | — | — | CN | disclosed |
| EP-2537859-A1 | Molecules specifically binding pancreatic beta cells biomarkers | Université de Mons (BE) | 2012-12-26 | — | — | EP | disclosed |
| EP-1759761-B1 | AFFINITY PARTICLE AND AFFINITY SEPARATION METHOD | SHISEIDO CO LTD (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-1750127-B1 | Method of affinity separation. | SHISEIDO CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20100137133-A1 | Affinity Particle And Affinity Separation Method | SHISEIDO COMPANY, LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20090321357-A1 | Affinity Particle And Affinity Separation Method | SHISEIDO COMPANY, LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090321358-A1 | Affinity Particle And Method Of Affinity Separation | SHISEIDO COMPANY, LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20070241054-A1 | Affinity Particle And Method Of Affinity Separation | SHISEIDO COMPANY, LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070181503-A1 | Affinity particle and affinity separation method | SHISEIDO COMPANY, LTD. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1759761-A1 | AFFINITY PARTICLE AND AFFINITY SEPARATION METHOD | SHISEIDO COMPANY, LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| EP-1750127-A1 | AFFINITY PARTICLE AND METHOD OF AFFINITY SEPARATION | Shiseido Company, Limited (JP) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090321357-A1 | Affinity Particle And Affinity Separation Method | FCGR1A, ACP1, FCGR3B | DGKA 2532/4885HTR2C 3792/4885ADRA2A 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.